ReviewDiscover oncology2026
Prognostic significance of serum iron panel in breast carcinoma: correlation with histopathological grading and molecular immunophenotypes.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast carcinoma is the most common malignancy in women globally, with prognosis significantly impacted by histopathological grading and molecular immunophenotypes. Iron metabolism dysregulation plays a crucial role in cancer progression, and serum iron panel components have emerged as potential prognostic biomarkers, aiding in disease assessment and management.
objectiveThis review aims to explore the prognostic significance of the serum iron panel in breast carcinoma and its correlation with histopathological grading and molecular immunophenotypes.
methodsA thorough literature review was performed using peer-reviewed articles from PubMed, Scopus, and Web of Science. Studies examining the relationship between serum iron parameters (serum iron, ferritin, transferrin saturation, and total iron-binding capacity) and breast carcinoma subtypes, histopathological grading, and molecular immunophenotypes were analyzed for inclusion.
resultsSerum iron parameters are altered in breast carcinoma but the results are heterogeneous. High ferritin levels are indicative of higher tumor grade, as well as increased tumor burden and poor outcomes. Transferrin saturation and TIBC exhibit different patterns. More aggressive subtypes, most notably triple-negative breast cancer, show greater iron dysregulation, suggesting a connection between iron metabolism and tumor characteristics despite inconsistencies in findings.
conclusionSerum iron biomarkers, such as ferritin, could indicate cancer aggressiveness and subtype in breast cancer. However, the evidence is inconsistent and mostly observational. These markers may be viewed as adjuncts rather than definitive prognostic tools and would benefit clinically best from validation via large-scale prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.